Sino Biopharmaceutical Limited (01177) announced on July 15, 2025, that its wholly-owned subsidiary, Zhengda Pharmaceutical Investment (Beijing) Group Co., Ltd., will acquire a 95.09% equity interest in LaNova Medicines. The transaction carries a maximum consideration of approximately US$951 million. After deducting LaNova's estimated cash and bank deposits of US$450 million at closing, the net payment required from the buyer amounts to roughly US$501 million.
Currently, the acquiring subsidiary holds a 4.91% stake in LaNova Medicines. Upon completion of the acquisition, Sino Biopharmaceutical will own 100% of LaNova, making it an indirect wholly-owned subsidiary.
LaNova Medicines represents a globally leading innovative drug R&D company specializing in tumor immunology and tumor microenvironment research. This strategic move substantially aligns with Sino Biopharmaceutical's innovation-driven and internationalization strategy. The acquisition is expected to significantly enhance the group's core competitiveness and global influence within the oncology innovation sector.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。